
Opinion|Videos|January 13, 2025
Identifying Patients With OSA
Author(s)Aneesa Das, MD , Jeanne Caligiuri, MD
Panelists discuss how health care providers can identify patients at risk for obstructive sleep apnea through screening tools, clinical history assessment, and recognition of key symptoms such as daytime sleepiness, loud snoring, and witnessed breathing pauses during sleep.
Advertisement
Episodes in this series

Advertisement
Related to this article

AHA 2026: Yoga-based cardiac rehabilitation improved quality of life and walking distance in patients with HFrEF but did not significantly reduce death, hospitalization, or stroke.

The ACS 2026 prostate cancer screening guidelines recommend risk-based PSA testing beginning at age 45 or 50, with updated follow-up thresholds.

Retatrutide trials report less knee osteoarthritis pain; ixekizumab plus tirzepatide shows exploratory ACR50 benefits in psoriatic arthritis.

Asundexian reduced relative ischemic stroke risk by 26% alongside antiplatelet therapy, with bleeding concerns in older adults.

Survodutide demonstrated cardiovascular safety vs placebo in the phase 3 SYNCHRONIZE-CVOT trial, with improvements in weight and cardiometabolic risk factors.

Evolocumab was associated with a 20% lower risk of fatal or nonfatal myocardial infarction than ezetimibe among more than 544 000 adults with ASCVD.

The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Asundexian for Stroke Prevention After Ischemic Stroke or TIA
2
Contraindicated Hormone Therapy Prescribing Climbs in Primary Care
3
Retatrutide Phase 3 Trials Report Reduced Knee Osteoarthritis Pain
4
New Study Shows Menopause Undercoded in Primary Care, With Gaps by Race and Insurance
5

